CYP3A4 Mediates Oxidative Metabolism of the Synthetic Cannabinoid AKB-48

AAPS Journal

Volumn 17, Issue 5, 2015, Pages 1237-1245

  Holm, Niels Bjerre ^a   Nielsen, Line Marie ^a   Linnet, Kristian ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

adamantyl; cytochrome P450; metabolism; metabolites; synthetic cannabinoids

Indexed keywords

ADAMANTANE DERIVATIVE; CANNABINOID; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; KETOCONAZOLE; N (1 ADAMANTYL) 1 PENTYL 1H INDAZOLE 3 CARBOXAMIDE; QUINIDINE; TICLOPIDINE; UNCLASSIFIED DRUG; ADAMANTANE; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 INHIBITOR; INDAZOLE DERIVATIVE; N-(1-ADAMANTYL)-1-PENTYLINDAZOLE-3-CARBOXAMIDE;

AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; CHEMICAL ANALYSIS; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIHYDROXYLATION; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; INSECT; KETOGENESIS; LIVER MICROSOME; NONHUMAN; TOXICITY TESTING; ANALOGS AND DERIVATIVES; METABOLISM; OXIDATION REDUCTION REACTION;

ADAMANTANE; CANNABINOIDS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INDAZOLES; MICROSOMES, LIVER; OXIDATION-REDUCTION;

EID: 84939568938     PISSN: None     EISSN: 15507416     Source Type: Journal    
DOI: 10.1208/s12248-015-9788-7     Document Type: Article

References (37)

1. Pertwee RG. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol. 2008;13(2):147–59.
2. Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N. ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44(5):832–7.
3. Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y. Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull (Tokyo). 2009;57(4):439–41.
4. Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y. URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int. 2013;227(1-3):21–32.
5. New psychoactive substances in Europe: An update from the EU Early Warning System (March 2015). European Monitoring Centre for Drugs and Drug Addiction. 2015. http://www.emcdda.europa.eu/publications/2015/new-psychoactive-substances. Accessed 6 May 2015.
6. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
7. Meyer MR, Peters FT. Analytical toxicology of emerging drugs of abuse—an update. Ther Drug Monit. 2012;34(6):615–21.
8. Wohlfarth A, Weinmann W. Bioanalysis of new designer drugs. Bioanalysis. 2010;2(5):965–79.
9. Castaneto MS, Scheidweiler KB, Gandhi A, Wohlfarth A, Klette KL, Martin TM, et al. Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Test Anal. 2014. doi:10.1002/dta.1709.
10. Hutter M, Broecker S, Kneisel S, Auwarter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques. J Mass Spectrom. 2012;47(1):54–65.
11. Chimalakonda KC, Bratton SM, Le VH, Yiew KH, Dineva A, Moran CL, et al. Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases. Drug Metab Dispos. 2011;39(10):1967–76.
12. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol. 2012;31(10):1006–11.
13. Holm NB, Pineda RS, Andersen DW, Rasmussen BS, Dalsgaard PW, Hoegberg L, et al. Screening of Danish traffic cases for synthetic cannabinoids in whole blood by LC-MS/MS. Scand J Forensic Sci. 2013;19(2):45–51.
14. Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, et al. Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos. 2012;40(11):2174–84.
15. Chimalakonda KC, James LP, Radominska-Pandya A, Moran JH. Sulfaphenazole and alpha-naphthoflavone attenuate the metabolism of the synthetic cannabinoids JWH-018 and AM2201 found in K2/spice. Drug Metab Lett. 2013;7(1):34–8.
16. Thomsen R, Nielsen LM, Holm NB, Rasmussen HB, Linnet K. Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Test Anal. 2014. doi:10.1002/dta.1731.
17. Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, et al. First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J. 2013;15(4):1091–8.
18. Holm NB, Pedersen AJ, Dalsgaard PW, Linnet K. Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test Anal. 2015;7(3):199–206.
19. Sobolevsky T, Prasolov I, Rodchenkov G. Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue. Drug Test Anal. 2015;7(2):131–42.
20. Gandhi AS, Wohlfarth A, Zhu M, Pang S, Castaneto M, Scheidweiler KB, et al. High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test Anal. 2015;7(3):187–98.
21. Grigoryev A, Kavanagh P, Melnik A. The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry. Drug Test Anal. 2012;4(6):519–24.
22. Bekendtgørelse om euforiserende stoffer. BEK 557 af 31/05/2011. Ministeriet for Sundhed og Forebyggelse. https://www.retsinformation.dk/Forms/R0710.aspx?id=138271#B1. Accessed 8 Apr 2015.
23. 2.5 Synthetic cannabinoids. In: 2013 Annual Report. National Forensic Laboratory Information System. 2014. https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS2013AR.pdf. Accessed 8 Apr 2015.
24. Illegale stoffer i Danmark. In: Illegale stoffer i Danmark, Årsrapport 2013. Sundhedsstyrelsen. 2014. https://sundhedsstyrelsen.dk/da/sundhed/narkotika/indhold-i-illegale-stoffer~/media/0F7441B6213B4FA3A8E874B00984B964.ashx. Accessed 8 Apr 2015.
25. Drug Development and Drug Interactions: Table of substrates, inhibitors and inducers. In: Development & approval process (drugs). U.S. Food and Drug Administration. 2014. http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm. Accessed 8 Apr 2015.
26. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol. 2000;49(4):343–51.
27. Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol. 2000;50(6):563–71.
28. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283(2):434–42.
29. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.
30. Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacol Ther. 2010;49(9):573–88.
31. Su H, Boulton DW, Barros Jr A, Wang L, Cao K, Bonacorsi Jr SJ, et al. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. Drug Metab Dispos. 2012;40(7):1345–56.
32. He H, Tran P, Yin H, Smith H, Batard Y, Wang L, et al. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009;37(3):536–44.
33. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci. 2001;58(5-6):737–47.
34. Forrester MB, Kleinschmidt K, Schwarz E, Young A. Synthetic cannabinoid exposures reported to Texas poison centers. J Addict Dis. 2011;30(4):351–8.
35. Zhou X, Gao ZW, Meng J, Chen XY, Zhong DF. Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs. Acta Pharmacol Sin. 2013;34(11):1420–6.
36. Dresen S, Ferreiros N, Putz M, Westphal F, Zimmermann R, Auwarter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom. 2010;45(10):1186–94.
37. Hudson S, Ramsey J, King L, Timbers S, Maynard S, Dargan PI, et al. Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in “herbal high” products. J Anal Toxicol. 2010;34(5):252–60.